Biotech Values

[HobGlobulin]

Re: Regado Biosciences

Regado has licensed aptamer technology from Archemix. The original PR was in 2003.

http://archemix.com/website/partnership_current.php

>> Archemix granted a license to Regado for the discovery and development of antidote-controlled aptamers. The REG1 anticoagulation system, which targets Factor IX, completed Phase 1 trials in 2006, the results of which were recently published (Circulation. 2006;114:2490-2497). REG1 is scheduled to begin Phase 2 trials in 2007. <<

Nuvelo is also on record licensing Archemix aptamers to target the coagulation cascade.

I believe Archemix, which announced a strategic alliance with Isis for aptamer development back in August, is planning to to become public.

Aptamers have been around a long time. Maybe the technology is finally advancing beyond the "promising but no products" stage.


Hob